TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05461222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balt Goldballoon
Description: Fetal endoscopic tracheal occlusion (FETO) is a procedure where a balloon is placed in the main airway or windpipe of the fetus, to help with the development of the lungs. This is performed using a fetoscope, a small camera that is inserted into the amniotic cavity and deploying the FETO Goldballoon into the fetal trachea.
Study: NCT06052371

Intervention type: DEVICE
Intervention: VerioVue (Enhancements) blood glucose monitoring system
Description: VerioVue meter with expanded haematocrit range
Study: NCT04756609

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systematic offer of nurse-driven SARS-CoV-2 screening combined with usual practice
Description: I- A SARS-CoV2 self-administered questionnaire about SARS-CoV2 symptoms, possibilities of close contacts, risk exposure situations and socio-demographic characteristics will be offered to patients included who are capable of filling it out.~* The patient will fill out the questionnaire and hand it in to the nurse caring for him/her.~* The nurse, regardless of the answers to the questionnaire, will offer the SARS-CoV2 screening.~* A nasopharyngeal swab for SARS-CoV2 will be carried out.~* A patient will be considered as symptomatic if he/she presents one or more symptoms listed in the questionnaire.~* For symptomatic patients, a SARS-CoV2 for multiplex PCR will be carried out. This analysis takes 75 minutes.~* For asymptomatic patients, a RT-LAMP test will be carried out. This analysis takes 5 to 15 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual emergency department practice with physician-directed diagnostic testing
Description: The physician offers a SARS-CoV2 test according to current recommendations. The tests are prescribed as a means of diagnosis for patients presenting symptoms suggestive of Covid-19 or as a means of diagnosis for patients requiring hospitalisation for another cause, before their transfer to hospital. Patients will be cared for according to usual procedures of each hospital. Patients tested positive will be asked to fill out the DEPIST-COVID questionnaire. Patients who had not completed it will be contacted by phone to answer the questions over the phone.
Study: NCT05786807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-CAB
Description: Tegoprazan 50 mg 1 tab twice daily Amoxicillin 500mg 2 cap twice daily Clarithromycin 500mg 1tab twice daily
Study: NCT04817592

Intervention type: PROCEDURE
Intervention: Corneal lenticule extraction for advanced refractive correction (CLEAR)
Description: Routinely conducted procedure for correction of Myopia

Intervention type: PROCEDURE
Intervention: Corneal lenticule extraction for advanced refractive correction (CLEAR)
Description: Routinely conducted procedure for correction of Myopia

Intervention type: PROCEDURE
Intervention: Corneal lenticule extraction for advanced refractive correction (CLEAR)
Description: Routinely conducted procedure for correction of Myopia

Intervention type: PROCEDURE
Intervention: Corneal lenticule extraction for advanced refractive correction (CLEAR)
Description: Routinely conducted procedure for correction of Myopia

Intervention type: PROCEDURE
Intervention: Corneal lenticule extraction for advanced refractive correction (CLEAR)
Description: Routinely conducted procedure for correction of Myopia
Study: NCT05751681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progestin primed ovarian stimulation protocol
Description: progestin primed ovarian stimulation protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: progestin primed ovarian stimulation protocol
Description: progestin primed ovarian stimulation protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dydrogesterone (Duphaston, Abbott)
Description: 20 mg oral dose of dydrogesterone (Duphaston, Abbott)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrotide
Description: 0.25 mg of Cetrotide (gonadotropin releasing hormone (GnRH) antagonist)
Study: NCT06358378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aktiia SA Bracelet
Description: The Aktiia device is a wearable blood pressure monitor developed by the company Aktiia SA. It is designed to monitor at blood pressure frequent intervals throughout the day and night without the need for inflatable cuffs. Instead, it contains optical sensors which collect photoplethysmography signals from arteries in the patient's wrist and uses these to estimate blood pressure. The device only takes measurements when it perceived optimal conditions for doing so, corresponding to minimal arm movement (i.e. a resting state) for at least five minutes and good quality signal detection. This device is commercially available and validated for use in adults aged 85 and younger.
Study: NCT06579521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: A standard dose of alcohol will be administered (volume calculated with regard to age, sex assigned at birth, height, and weight) in the form of vodka and combined with mixer at a 1:4 ratio to reach a target breath alcohol concentration of .08%.
Study: NCT06578910

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard of care
Description: 12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.

Intervention type: OTHER
Intervention: Patient satisfaction questionnare
Description: VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
Study: NCT05211388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA controlled using echo decorrelation imaging
Description: The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, with echo decorrelation imaging providing an additional stopping criterion.~The targeted ablation zone will be subdivided into one or more contiguous control subvolumes encompassing the tumor. An echo decorrelation threshold will be chosen to provide a target specificity (e.g. 90%) for local ablation prediction, based on ROC curve analysis for ablation prediction in clinical RFA and MWA as well as in controlled ablation of ex vivo human liver tumors. Controlled RFA treatments will proceed until the average cumulative decorrelation exceeds this predetermined threshold within each control subvolume.~To avoid compromising patient safety, treatments will not be extended beyond manufacturer-specified end points.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA controlled using standard manufacturer-specified algorithms
Description: The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, e.g. based on temperatures measured by thermocouples integrated into the RFA probe. 3D echo decorrelation imaging will be performed in real time during ablation, but will not be used to modify treatments.
Study: NCT05956288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) with low load resistance training
Description: Combination of low load resistance exercise in the upper limb with the addition of blood flow restriction or sham-blood flow restriction.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Blood flow restriction (BFR) with low load resistance training
Description: Combination of low load resistance exercise in the upper limb with the addition of blood flow restriction or sham-blood flow restriction.
Study: NCT04909242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive DZD9008 at different dose levels. There are 5 planned dose cohorts, starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008 or matching placebo, namely 100 mg, 200 mg, 300 mg and 400 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive matching placebo for DZD9008 at different dose levels. There are 5 planned dose cohorts of matching placebo for DZD9008, starting from 50 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: In Part C, healthy adult participants will be enrolled to receive a single dose of DZD9008 as suspension in period 1 and as tablet in period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: Healthy adult participants will be randomized to receive DZD9008 single dose at a defined dose under a cross-over condition with or without food (low-fat in Part B; high-fat in Part D).
Study: NCT05964478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-component hand hygiene intervention in primary schools not connected to functional water supply system in Nigeria and Palestine
Description: Each participating school receives: (i) Two Gravit'eau handwashing stations (http://www.graviteau.ch): these systems recycle on-site greywater and operate through gravity and a manual foot pump, and can be produced locally. (ii) Behavior change activities: Developed by a group of expert psychologists (http://www.ranasmosler.com/ranas), utilizing the risks, attitudes, norms, abilities, and self-regulation (RANAS) approach. (iii) WASH infrastructure rehabilitation and soap dispenser installation. (iv) Controlled chlorine monitoring: Equipment provided for monitoring chlorine concentration in water storage, with staff training. (v) Preventive maintenance: Trained circuit rider inspects infrastructure regularly under WASH committee supervision
Study: NCT05439798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron+Dexamethasone
Description: The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron+Dexamethasone
Description: The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone
Study: NCT05680220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostimulation System (NSS): Active Setting
Description: Exposure to the active device for 1 hour a day for 6 weeks
Study: NCT05564013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Up to 25 minutes of virtual reality exposure in supine position
Study: NCT05586568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621 tablet and itraconazole oral liquid (for Arm1)
Description: There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1. For period 2,the subjects will take itraconazole from Day11 to Day13，they will take itraconazole in combinaiton with XZP-3621 on Day14，then take itraconazole only, from Day15 to Day27.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621 tablet and Rifampicin capsules (For Arm 2)
Description: There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets qd on Day1 . For period 2,the subjects will take Rifampicin from Day11 to Day17，they will take Rifampicin in combinaiton with XZP-3621 on day18，then take Rifampicin only, from Day19 to Day26.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621 tablet and esomeprazole tablet (For Arm3)
Description: There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1 . For period 2,the subjects will take esomeprazole from Day11 to Day 15，they will take esomeprazole in combinaiton with XZP-3621 on Day16.
Study: NCT05777330

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oral glucose tolerance test (OGTT)
Description: Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in first-degree relatives at moderate, high and very high risk of clinical onset of type 1 diabetes.~OGTT is performed every 6 months (every 3 months in case of dysglycemia) in all participants.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hyperglycemic clamp test
Description: Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in first-degree relatives at moderate, high and very high risk of clinical onset of type 1 diabetes.~Clamp test is performed every 12 months in single autoantibody-positive participants and every 6 months in multiple autoantibody-positive participants. Clamp tests are not performed in participants aged between 5-11 years.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Continuous glucose monitoring
Description: Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in first-degree relatives at moderate, high and very high risk of clinical onset of type 1 diabetes.~A 10-day CGM recording is performed every 6 months (every 3 months in case of dysglycemia) in all participants.
Study: NCT04846959

Intervention type: DRUG
Intervention: Risankizumab
Description: Subcutaneous Injection

Intervention type: DRUG
Intervention: Comparator
Description: Subcutaneous or Intravenous Injection
Study: NCT04741308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavior therapy
Description: The CBT intervention is a 8-times group-based intervention that meets 2-3 weeks.Each session will be performed during chemotherapy and will last for 60 min, including 45 min cognitive behavior therapy and 15 min relaxation training.Our CBT intervention is designed to be conducted in groups of 3 to 6 patients led by two group facilitators. Group leaders will: guide participants relaxation training, develop a supportive group environment, encourage emotional expression, assist participants develop a sense of self-confidence, identify maladaptive coping and encourage adaptive coping responses.
Study: NCT05661955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: administered intravenously
Study: NCT06100237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered per discretion of treating physician. Participants will receive the recommended dosage.
Study: NCT05680220

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neurostimulation System (NSS): Sham Setting
Description: Exposure to the sham device for 1 hour a day for 6 weeks
Study: NCT05388643

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Enhanced First Trimester GDM Screening
Description: Women who are randomly assigned to this condition will be required to have early glucose screening with a prediction model composed of additional clinical risk factors and serum biomarkers (triglycerides, PAPP-A, and lipocalin-2) with their initial prenatal laboratory assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Routine Gestational Diabetes Screening
Description: Women who will be randomized to the comparison condition of usual standard of care will undergo routine standard of care. The standard of care will consist of routine screening for diabetes in pregnancy between 24 to 28 weeks of gestation via the two-step screening method with possible early screening with either plasma fasting glucose, oral glucose tolerance test, or hemoglobin A1c at the providers discretion to represent true clinical practice.
Study: NCT03266315

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FloraBaby
Description: 1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
Study: NCT05619354

Intervention type: OTHER
Intervention: Survey study
Description: Participants will be asked to complete and evaluate the Dutch version of the Headache Disability Index. Validity (face validity, content validity, convergent validity with the RAND-36 and HIT-6) will be determined. Second, internal consistency and test-retest reliability will be evaluated.
Study: NCT05661955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: administered intravenously
Study: NCT05349656

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TQL block
Description: Ultrasonography-guided quadratus lumborum block (QLB) where we will infiltrate local anesthetic solution adjacent to the anterolateral aspect of the quadratus lumborum muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG block
Description: Ultrasound-guided local anesthetic infiltration will be injected in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly
Study: NCT05661955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered intravenously
Study: NCT05400343

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care (control group)
Description: Following 24 hours from admission to the ICU, the standard care will be continued according to conventional ICU protocols~The mean fluid intake will range from (2-3L per day) targeting zero or slightly negative balance (up to - 300ml). Various parameters will be used to attain this goal based on case-by-case clinical judgment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-guided ﬂuid management (active group)
Description: Within 24 hours from admission to the ICU, IVC and lung sonography will be performed every other day and according to their measurements, the volume of fluid therapy will be adjusted.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ICU Care
Description: All patients will receive the usual care for 24 hours according to ICU policies. The main target is to maintain an adequate intravascular volume and good urine output. The mean fluid intake will range from (2-3L per day) targeting zero or slightly negative balance (up to - 300ml). Various parameters will be used to attain this goal based on case-by-case clinical judgment. Lung sounds, heart rate, blood pressure, temperature, urine output, Lactate, haemoglobin, haematocrit, serum urea, creatinine, sodium, potassium, chloride, and bicarbonate values

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard ICU Care
Description: All patients will receive the usual care for 24 hours according to ICU policies. The main target is to maintain an adequate intravascular volume and good urine output. The mean fluid intake will range from (2-3L per day) targeting zero or slightly negative balance (up to - 300ml). Various parameters will be used to attain this goal based on case-by-case clinical judgment. Lung sounds, heart rate, blood pressure, temperature, urine output, Lactate, haemoglobin, haematocrit, serum urea, creatinine, sodium, potassium, chloride, and bicarbonate values
Study: NCT06571266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: • Subcutaneous Injection via prefilled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: • Subcutaneous Injection via prefilled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: • Subcutaneous Injection via prefilled syringe
Study: NCT06100237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab SC
Description: Daratumumab SC will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
Study: NCT04286139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHAPE
Description: The SHAPE intervention provides information for carers, and maintains the dignity and autonomy of the person with dementia, supporting them in planning for the future with their family. The person with dementia attends an online 10 week facilitator lead group based course. It is designed to develop self-management skills in areas including decision-making, symptom management and social interaction. It also provides information on the disease process and the development of healthy behaviors in a supportive learning environment to prevent problems that are common in the later stages of the disease. The adjunctive e-learning platform for carers provides the same information that the person with dementia receives plus additional material and signposting to support them in their role. This will empower the whole family to support and enable more effective self-management by the person with dementia, and enhance their ability to plan ahead together and make key decisions jointly.